Mechanism of Sorafenib-Induced Skin Tumors Proposed
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Skin Tumors Induced by Sorafenib; Paradoxical RAS-RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53 and TGFBR1
Clin. Cancer Res 2011 Nov 17;[EPub Ahead of Print], JP Arnault, C Mateus, B Escudier, G Tomasic, J Wechsler, E Hollville, J-C Soria, D Malka, A Sarasin, M Larcher, J Andree, N Kamsu-Kom, L Boussemart, L Lacroix, A Spatz, A Eggermont, S Druilenec, S Vagner, A Eychene, N Dumaz, C RobRenal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.